Released Jun 15, 2020, after the close
10-Q filed Jun 15, 2020, 46 days after period end · 0001654954-20-006640
Q2 2020 · 10-Q
Revenue$5.65M$5.65M +9.7% vs Q2 2019+22.4% vs Q1 2020
Net Income$687.56K$687.56K −2.8% vs Q2 2019+30.5% vs Q1 2020
EPS, diluted—
Gross Profit$1,868,900+17.3%
Operating Income$720,384+51.0%
Operating Cash Flow-$1,556,707N/M
Free Cash Flowderived-$1,584,255N/M
Margins · derived
Gross margin33.1%+2.2 pt vs Q2 2019
Operating margin12.8%+3.5 pt vs Q2 2019
Net margin12.2%−1.6 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $5.65M | $5.15M | $3.77M | $3.92M |
| Net Income | $687.56K | $707.48K | -$128.35K | -$322.76K |
| EPS Diluted | — | — | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR